Driving Biologics Formulation Through Digital And In Silico Transformation

Dr. Tim Menzen, Chief Technology Officer and Dr. Andrea Arsiccio, Senior Scientist/ Team Lead in Silico

Digital transformation is reshaping biologics formulation by bringing advanced computational tools, such as generative AI, machine learning, and natural language processing, into the earliest stages of development. These technologies allow teams to evaluate molecules during late discovery, identifying key biophysical properties and potential liabilities long before traditional methods can. Early insights help developers prioritize stronger candidates, reduce technical risks, and move more efficiently toward stable, manufacturable drug products.

This shift reflects a broader technological evolution across the life sciences, driven by growing computing power, improved visualization tools, and recent advances in protein design and prediction. Breakthroughs in computational protein modeling now enable formulation scientists to better predict molecular behavior, assess manufacturability, and anticipate challenges without requiring physical material. As these digital and in‑silico approaches become more integrated into preclinical workflows, they are redefining how biologic therapies are designed, evaluated, and prepared for clinical development—ultimately accelerating the path from discovery to the clinic.